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Abstract 
Background: The Korean Health Insurance Review and Assessment Service (HIRA) has launched the Chronic 
Obstructive Pulmonary Disease (COPD) Quality Assessment Program (CQAP) since 2014. We aimed to reveal the influ‑
ence of this national program on clinical outcomes and the burden of COPD in Korea.
Methods: The CQAP is conducted annually. We used healthcare claims data linked with the results of the program 
provided by HIRA between May 2014 and April 2017. Patients were considered to have COPD if they visited a hospi‑
tal for COPD management during the assessment term. Those who visited a medical institution for COPD and were 
prescribed COPD medications at least twice were assessed by the CQAP (assessed subjects, AS; not‑assessed subjects, 
NAS). CQAP evaluated the pulmonary function test conduction rate, regular visitation rate, and prescription rates of 
COPD medications.
Results: Among the 560,000 patients with COPD, about 140,000 were assessed by the CQAP annually. In both 
groups, the pulmonary function test conduction rate and inhaled bronchodilator prescription rate improved since 
2014. Compared to the NAS group, the risk of admission and all‑cause mortality rate in the AS group were significantly 
reduced by 21.2% and 40.7%, respectively. In patients who were assessed for 3 consecutive years, all of the above 
variables were high at baseline and were not improved much from implementation of CQAP. In matching analysis, we 
observed this improvement to be limited in the COPD quality assessment year.
Conclusions: The CQAP by the health insurance bureau has improved the management protocol and prognosis of 
COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a 
chronic airway inflammatory disease characterized by 
a progressive decline in lung function [1, 2]. Therefore, 
affected patients require close monitoring of symp-
toms and pulmonary function and engagement in active 
medical treatment with bronchodilator-based regimen 
[3]. The worldwide prevalence of COPD is 10.1% with 
the number of patients continuously increasing, and it 
also increase the socioeconomic burden [4, 5]. Pulmo-
nary function tests (PFTs) are essential for the diagno-
sis and follow-up of COPD, and a low  FEV1 can predict 
a poor prognosis such as future deterioration. Therefore, 
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The Korean Health Insurance Review and Assessment 
Service (HIRA) has conducted the national Asthma 
Quality Assessment Program since 2013 to improve 
the practical management and clinical outcomes of 
asthmatics [6], and the results of it showed that regu-
lar follow-up visits significantly reduced the risk for 
asthma exacerbation [7]. In 2014, HIRA initiated the 
National COPD Quality Assessment Program (CQAP) 
to minimize the national burden of COPD and achieve 
the optimal treatment strategy to improve the qual-
ity of medical services for COPD in Korea. The CQAP 
assessed several parameters in Korean medical insti-
tutions with the following protocol: (a) regular lung 
function monitoring, (b) regularly visiting, (c) inhaled 
bronchodilator prescription for COPD patients, (d) 
admission rate, and (e) emergency department visita-
tion rate. Although the annual CQAP results have been 
released to the public, the direct and indirect impact 
of this program on clinical practice has not yet been 
estimated.
In this study, we investigated the influence of the 
CQAP on the treatment behavior of clinicians manag-
ing COPD, the clinical outcomes of COPD patients, 
and the national burden of COPD in Korea.
Methods
The National COPD Quality Assessment Program
The CQAP was proposed by the Korean government 
in 2014 and is conducted annually to (a) evaluate how 
COPD patients are treated in all Korean medical insti-
tutions; (b) improve the quality of COPD management 
protocols in clinics; and (c) improve the clinical out-
comes and prognosis of COPD patients. It evaluates the 
following: (1) PFT conduction at least once during the 
1-year assessment term; (2) regular follow-up visitation 
rate of COPD patients (i.e., at least three visits during 
the assessment term); and (3) inhaled bronchodilator 
prescription rate. The inhaled bronchodilator includes 
LAMA, long-acting β2 agonists (LABA), short-acting 
β2-agonists (SABA), a LABA + LAMA combination, 
and a LABA + inhaled corticosteroid combination 
drug.
After excluding institutions with < 10 COPD patients, 
HIRA rated all medical institutions according to five 
grades (1–5, with a lower number indicating better 
COPD management) in accordance with the overall 
score of the CQAP results (100–80, 1st grade; 80–65, 
2nd grade; 50–65, 3rd grade; 50–35, 4th grade; < 35, 5th 
grade). The overall score was calculated by a weighted 
average of the PFT conduction rate (40%), proportion of 
patients with regular follow-up (20%), and inhaled bron-
chodilator prescription rate (40%).
Data extraction from claims data linked with the CQAP
Korea has a unique national health insurance system cov-
ering all 50 million Korean people. Therefore, records 
of medical use, prescribed medications, and tests per-
formed are included in the claims data. We extracted 
data from May 1, 2014 to April 30, 2017.
Definition of COPD patients from HIRA claims data
COPD patients were defined as those who visited a medi-
cal institution (outpatient and/or inpatient department) 
at least once during the assessment term to manage his/
her COPD. COPD patients who met the following cri-
teria during the assessment term were assessed by the 
CQAP, and they were called as assessed subjects (AS): (1) 
age ≥ 40 years; (2) ICD-10 codes for COPD (J43, emphy-
sema and J44, other COPD) as the primary diagnosis or 
first sub-diagnosis; and (3) at least two separate outpa-
tient visits with the prescription of COPD medications 
or at least one admission for treatment with systemic 
steroids followed by outpatient visits. In 2014, this case 
definition of AS (for COPD) was established by the HIRA 
committee according to the opinions of respiratory and 
critical care experts in Korea. Since then, this definition 
has been widely used by many researchers and data ana-
lysts [8, 9]. COPD patients who did not meet the above 
criteria were not assessed by the CQAP, and they were 
classified as not-assessed subjects (NAS).
Determination of clinical outcomes
We defined the clinical outcomes as follows: (a) the num-
ber of admissions for treatment in a medical institution 
because of COPD exacerbation (with the ICD-10 codes 
of COPD [J43 and J44]); and (b) the yearly all-cause mor-
tality rate.
Study designs
Figure 1a briefly depicts the study design and numbers of 
patients included in this study. We applied four different 
study models to analyze the CQAP results (Fig. 1b). First, 
we selected the AS in each year. Next, the NAS groups 
were created. The CQAP results of the six groups were 
evaluated and compared at each assessment term. Then, 
we calculated the risk reduction rate over a 3-year period 
in the AS group compared with that in the NAS group 
using the following equation: 1-(relative increase in risk 
in the AS over 3  years/relative increase in risk in the 
NAS over 3 years), with a higher positive value indicat-
ing positive risk reduction effects of the CQAP in the AS 
group compared with those in the NAS group. Second, 
we selected a subgroup of patients assessed by the CQAP 
for 3 consecutive years and compared their serial annual 
outcomes. Third, we performed a matching analysis to 
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Fig. 1 Venn diagram for the COPD population included in this study (a) and conceptual diagrams showing four difference study designs (b). COPD, 
chronic obstructive pulmonary disease
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compare the sequential changes of the CQAP parameters 
and clinical outcomes of the same patients in 2014 and 
2016. To minimize the confounding factors, age, sex, and 
type of medical institution visited were matched. Fourth, 
we compared the CQAP results and clinical outcomes 
of “1st grade” medical institutions (overall CQAP score: 
100–80 points) versus “5th grade” institutions (over-
all CQAP score < 35 points) in the AS and NAS groups, 
annually from 2014 to 2016. Patients who did not visit 
any institution or who visited both "1st grade" and "5th 
grade" institutions were excluded in this design.
Ethics requirements
The Institutional Review Board of Severance Hospi-
tal (Number: 4-2018-0956) approved this study with a 
waiver for the acquisition of informed consent because of 
the minimal risk to patients.
Statistical analyses
We compared demographic data, medical use behav-
iors, and clinical outcomes between groups using the 
χ2 test (for categorical variables), independent sample 
t-test, and analysis of variance test (for continuous vari-
ables). To estimate and compare the risk reduction rate 
over 3 years between the AS and NAS groups, we used 
a generalized linear model. Propensity score matching 
was used to reduce the imbalance of age, sex, and types 
of medical institutions. Data were analyzed using SAS 
Enterprise version 6.1 (SAS Institute Inc., Cary, NC, 
USA). A P-value < 0.05 was considered to indicate statis-
tical significance.
Results
Demographic data, clinical practice parameters, 
and prognosis of all COPD patients
A total of 569, 253 (2014), 557,682 (2015), and 539,708 
(2016) COPD patients were recorded in the HIRA claims 
data. (Mean age: 67.5–68.2 years, Male: 60%). PFT con-
duction rates and inhaled LAMA and LABA prescription 
rates increased steadily each year, while SABA prescrip-
tion rates steadily decreased for all COPD patients over-
all (all P-values < 0.001). (Table 1).
Study population
Of the 560,000 COPD patients, approximately 142,000 
(25.5%) were annually assessed by the CQAP. Approxi-
mately 40% of all COPD patients were evaluated by the 
CQAP at least once over the 3  years. Moreover, 10% of 
all patients were assessed for all 3 consecutive years 
(Fig. 1a).
Demographic data, clinical practice parameters, 
and prognosis in the AS and NAS groups
In the AS groups, the PFT conduction rate increased 
from 60.2% to 69.0%, the inhaled LAMA prescription 
rate increased from 45.1% to 51.8%, and the inhaled 
LABA prescription rate increased from 49.4% to 53.4% 
(all P < 0.001). In the NAS groups, the PFT conduc-
tion rates were significantly lower than those in the AS 
groups; however, the rate increased from 24.8% to 27.8% 
(all P < 0.001). Similarly, the inhaled LAMA and LABA 
prescription rates in the NAS groups were also signifi-
cantly lower than those in the AS groups (all P < 0.001). 
Table 1 Demographics, clinical practice parameters, and prognosis of all COPD patients
SD, standard deviation; PFT, pulmonary function test; LAMA, long-acting muscarine antagonist; LABA, long-acting β2 agonist; ICS, inhaled corticosteroid; SABA, short-
acting β2 agonist
Medical cost was calculated using exchange rate between dollar and Korean won (KRW) in Jan 1st 2020 (1 dollar = 1167.5 KRW)
Year 2014 2015 2016
COPD patients in HIRA claim data n = 569,253 n = 557,682 n = 539,708
Demographics
 Age, mean ± SD 66.8 ± 13.2 67.5 ± 13.2 68.2 ± 13.2
 Sex, male (%) 349,505 (61.4) 341,160 (61.2) 328,170 (60.8)
Clinical practice parameters
 PFT conduction (%) 191,465 (33.6) 206,519 (37.0) 208,952 (38.7)
 Inhaled LAMA prescription (%) 78,044 (13.7) 90,871 (16.3) 94,501 (17.5)
 Inhaled LABA prescription (%) 144,130 (25.3) 153,830 (27.6) 148,101 (27.4)
 ICS prescription (%) 305,744 (53.7) 295,227 (52.9) 283,804 (52.6)
 SABA prescription (%) 90,031 (15.8) 69,349 (12.4) 67,717 (12.6)
Prognosis
 Frequency of admission for COPD /yr, mean ± SD 0.146 ± 0.773 0.147 ± 0.791 0.162 ± 0.869
 Medical cost for COPD management, mean ± SD (USD) 335.5 ± 1665.2 375.7 ± 1943.6 423.2 ± 2124.7
 All‑cause mortality in the next year (%) 17,950 (3.2) 21,114 (3.8) 23,417 (4.3)
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In contrast, the admission frequencies for COPD and all-
cause mortality rates in the AS groups were higher than 
those in the NAS groups (Table 2).
Comparison between the changes in CQAP parameters 
and risk reduction rate over 3 years
PFT conduction rates and inhaled LAMA and LABA pre-
scription rates increased over the 3 years for both groups. 
Significant changes in the clinical practice and prescrip-
tion pattern for most COPD medications (except ICS) 
were observed in both groups. Furthermore, although the 
admission frequency because of COPD slightly decreased 
in the AS group over the 3  years (−3.6%), it increased 
in the NAS group (+ 22.0%) (risk reduction rate, 21.2%; 
P < 0.001). Finally, the all-cause mortality rate greatly 
increased in the NAS group over the 3  years (+ 65.2%), 
whereas it very slightly decreased in the AS group 
(−0.3%) (risk reduction rate, 40.7%; P < 0.001) (Table 3).
Serial changes in clinical practice parameters 
and prognosis in patients assessed by the CQAP for 3 
consecutive years
Almost all of the above-mentioned CQAP variables 
related to clinical practice were high at baseline and 
remained constant over the assessment period in 
those evaluated by the CQAP over 3 consecutive years. 
However, the ICS prescription rate decreased and the 
admission frequency significantly increased (Table 4).
Matching analyses
Matching analyses were conducted in the NAS-2016 and 
AS-2016 groups (n = 127,927, respectively) and NAS-
2014 and AS-2014 groups (n = 137,402, respectively). 
Although the PFT conduction rate and inhaled LAMA 
prescription rate in matched AS-2016 patients peaked in 
2016, they decreased to the level of them in 2017. How-
ever, the admission frequency in the matched AS-2016 
patients increased in 2016 and continued increasing in 
2017. In contrast, the above values were not greatly influ-
enced by the assessment term in the matched NAS-2016 
group (Fig.  2a–c). Similar results were observed in the 
matching analyses between the NAS-2014 and AS-2014 
groups (Figs. 2d–f).
Comparison of clinical practice parameters 
with the prognosis of COPD patients according 
to the grade of the medical institution regularly visited
In the AS groups, COPD patients who visited the “1st 
grade” medical institutions reported higher PFT con-
duction rates and an improvement of this rate (81.6% to 
84.0%) than those who regularly visited the “5th grade” 
institutions (3.4% to 3.3%). Rates of inhaled LAMA 
Table 2 Demographics, clinical practice parameters and prognosis of study groups
AS, assessed subjects; NAS, not-assessed subjects; SD, standard deviation; PFT, pulmonary function test; LAMA, long-acting muscarine antagonist; LABA, long-acting 
β2 agonist; ICS, inhaled corticosteroid; SABA, short-acting β2 agonist
















 Age, mean ± SD 69.9 ± 10.1 65.8 ± 13.9 70.0 ± 10.1 66.7 ± 14.0 70.1 ± 10.1 67.5 ± 14.1
 Sex, male (%) 101,795 (71.8) 247,710 (57.9) 103,882 (72.8) 237,278 (57.2) 106,664 (74.4) 221,506 (55.9)
Clinical practice parameters
 PFT conduction (%) 85,392 (60.2) 106,073 (24.8) 91,084 (63.8) 115,435 (27.8) 98,895 (69.0) 110,957 (27.8)
 Inhaled LAMA 
prescription (%)
63,932 (45.1) 14,112 (3.3) 69,833 (48.9) 21,038 (5.1) 74,254 (51.8) 20,247 (5.1)
 Inhaled LABA pre‑
scription (%)
70,091 (49.4) 74,039 (17.3) 76,597 (53.6) 77,233 (18.6) 76,508 (53.4) 71,593 (18.1)
 ICS prescription (%) 82,331 (58.1) 223,413 (52.3) 81,284 (56.9) 213,943 (51.6) 81,242 (56.7) 202,562 (51.1)
 SABA prescription 
(%)
51,066 (36.0) 38,965 (9.1) 30,158 (21.1) 39,191 (9.5) 29,931 (20.9) 37,786 (9.5)
Prognosis




0.307 ± 1.062 0.091 ± 0.634 0.281 ± 1.002 0.100 ± 0.695 0.296 ± 1.065 0.111 ± 0.777
 All‑cause mortality 
in the next year 
(%)
8278 (5.8) 9672 (2.3) 8217 (5.8) 12,897 (3.1) 8341 (5.8) 15,076 (3.8)
Page 6 of 10Park et al. Respir Res           (2021) 22:87 
prescription were also higher among the former patients 
than among the latter patients. However, the mean 
admission frequency because of COPD was higher 
among patients who visited “1st grade” institutions than 
among the patients who visited “5th grade” institu-
tions (P < 0.001). The all-cause mortality rate was higher 
among the former patients than among the latter patients 
(P < 0.001). The mean risk ratio of mortality to admission 
frequency for the 3  years was about four times higher 
among the former patients than among the latter patients 
(Fig. 3).
Discussion
The CQAP conducted by HIRA in Korea is a govern-
ment-driven specific disease-oriented management qual-
ifying program. It aims to assess the level of management 
protocols achieved for COPD patients in all medical 
institutions in Korea. HIRA publishes the results of the 
CQAP annually with information regarding the COPD 
management quality of each medical institution and rat-
ings from “grade 1” to “grade 5” [10]. In this study, we 
revealed that the Korean CQAP positively influenced 
the quality of COPD medical services. Since the start of 
this program in 2014, the PFT conduction and inhaled 
bronchodilator prescription rates have steadily increased. 
Furthermore, these improvements were greater in the AS 
group than in the NAS group. It can be assumed that the 
CQAP has some influence on clinicians’ practices and 
patients’ medical use behavior in real-world settings.
The CQAP also influenced COPD management and 
prognosis. This phenomenon appeared differently in the 
AS and NAS groups. Every year, the CQAP data showed 
that the percentage of prescribed bronchodilators in the 
AS group was higher than that in the NAS group. Every 
year, the it also showed that the admission rate of patients 
in the AS group because of COPD was higher than that 
of patients in the NAS group; the mortality rate was also 
higher in the AS group. It is thought that patients with 
more severe COPD were included in the AS group than 
in the NAS group. We speculate that this phenomenon 
is because the coverage of medical insurance increased 
with national income and the interest in the health of 
Table 3 Comparison between the changes in CQAP parameters and risk reduction rate over 3 years
AS, assessed subjects; NAS, not-assessed subjects; PFT, pulmonary function test; LAMA, long-acting muscarine antagonist; LABA, long-acting β2 agonist; ICS, inhaled 
corticosteroid; SABA, short-acting β2 agonist




 PFT conduction rate  + 14.6%  + 12.1% − 2.4%  < 0.001
 Inhaled LAMA prescription rate  + 14.9%  + 54.5%  + 25.8%  < 0.001
 Inhaled LABA prescription rate  + 8.1%  + 4.6% − 3.5%  < 0.001
 ICS prescription rate − 2.4% − 2.2%  + 0.2%  < 0.001
 SABA prescription rate − 41.9%  + 4.4%  + 44.6%  < 0.001
Prognosis
 Frequency of admission for COPD − 3.6%  + 22.0%  + 21.2%  < 0.001
 All‑cause mortality in the next year − 0.3%  + 65.2%  + 40.7%  < 0.001
Table 4 Serial changes of clinical practice parameters and prognosis in subjects assessed by CQAP for consecutive 3 years
AS, assessed subjects; PFT, pulmonary function test; LAMA, long-acting muscarine antagonist; LABA, long-acting β2 agonist; ICS, inhaled corticosteroid; SABA, short-
acting β2 agonist
Year 2014 2015 2016 3‑year changes
Overlapping patients in AS group for 3 years n = 59,519 n = 59,519 n = 59,519 (%)
Clinical practice parameters
 PFT conduction (%) 40,258 (67.6) 39,390 (66.2) 40,831 (68.6)  + 1.5
 Inhaled LAMA prescription (%) 36,700 (61.7) 37,851 (63.6) 36,907 (62.0)  + 0.5
 Inhaled LABA prescription (%) 35,746 (60.1) 37,800 (63.5) 36,656 (61.6)  + 2.5
 ICS prescription (%) 33,468 (56.2) 32,118 (54.0) 32,231 (54.2) ‑3.6
 SABA prescription (%) 15,029 (25.3) 14,248 (23.9) 14,516 (24.4) ‑3.6
Prognosis
 Frequency of admission for COPD/yr, mean ± SD 0.288 ± 0.923 0.277 ± 0.969 0.372 ± 1.260  + 29.2
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chronically ill patients increased. Additionally, because of 
the natural course of COPD, the mortality rate of severely 
ill patients is inevitably high.
However, when analyzing the results for 3  years in 
a row, the hospitalization and mortality rates in the AS 
group slightly decreased, while in the NAS group both 
rates increased significantly. The risk reduction rates 
of the AS group for this result were 21.2% and 40.7%, 
and thorough COPD management through the CQAP 
played a major role. The guidelines suggest that the use 
of inhaled bronchodilators has a positive effect on the 
management and prognosis of COPD patients, but they 
are not widely used in practice in Korea. This implies that 
both clinicians and patients need to change their percep-
tions about long-term management goals of COPD [11]. 
Additionally, it is well known that periodic monitor-
ing using PFTs can predict a patient’s prognosis, but it 
is doubtful whether they are performed in real practice 
situations [12].
To reduce the socioeconomic burden of chronic ill-
nesses, the physicians managing chronic illnesses should 
manage patients in the most efficient way possible (with 
regards to factors such as guidelines and action plans), 
and patients should show a high degree of adherence to 
the control and rescue medications [13, 14]. The CQAP 
is considered a new model for inducing changes in the 
behavior of doctors and patients. For asthma, HIRA 
has been conducting the Asthma Quality Assessment 
Program (AQAP) since 2013. A 4-year AQAP analysis 
showed that the risk reduction rates of admission fre-
quency because of asthma exacerbation and all-cause 
mortality rate of the patients observed by AQAP (AS 
group) were 17.1% and 24.4%. when compared with not 
assessed subjects (NAS group) [15]. These were lower 
than those of COPD because the decline in lung function 
and irreversible changes are more severe in COPD than 
in asthma, and the probability of systemic co-morbidity is 
higher in COPD.
However, weak effects were observed in the subgroup 
assessed by the CQAP for 3 consecutive years. This sub-
group had higher PFT conduction and prescription rates 
of LABA and LABA inhalers at baseline. A higher admis-
sion frequency was found compared to those in the NAS 
group. This subgroup required multiple COPD medica-
tions and was highly dependent on high-quality (upper 
rather than secondary hospital) medical services, imply-
ing that this subgroup experienced more severe COPD. 
Unfortunately, this group did not much improvement.
Additionally, the positive effects of the CQAP may be 
temporary. In the matching analysis, the PFT conduction 
Fig. 2 Matching analyses. Comparison of annual changes in the PFT conduction rate (a), inhaled LAMA prescription rate (b), and admission 
frequency (c) between those patients assessed by CQAP and matched patients that were not assessed in 2016. Comparison of annual changes in 
the PFT conduction rate (a), inhaled LAMA prescription rate (b), and admission frequency (c) between patients assessed by CQAP and matched 
patients that were not assessed in 2014. PFT, pulmonary function test; COPD, chronic obstructive pulmonary disease. CQAP, COPD quality 
assessment program
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and LAMA prescription rates of the AS-2016 group 
showed a sharp decrease in 2017. Such a phenomenon 
was also observed in the AS-2014 group. This means that 
government-led policies alone have limits to the duration 
of effects on the positive behavior changes of physicians. 
Therefore, in continuously operating programs such as 
the CQAP, through the close cooperation with academia 
as a private sector, doctors themselves can autonomously 
modify their practices for improvement.
HIRA classify all medical institutions in Korea into five 
grades considering management protocol of COPD, and 
made this information publicly available. We can expect 
1st grade institutions show better practice performance 
the compared to the 5th grade institutions, however, the 
hospitalization and mortality rates increased as the grade 
of the institution decreased (5th to 1st grade). This can be 
explained by considering the size of the medical institu-
tions and the severity of COPD. Overall, Korean COPD 
patients are more likely to be treated by higher-level 
institutions for more severe illnesses because of con-
tinuous pulmonary dysfunction, and are monitored and 
managed according to global guidelines. Therefore, how 
CQAP guides mild-to-moderate patients to be treated 
and monitored according to guidelines at 3rd-, 4th-, and 
5th-grade institutions is the main question to be focused 
in the future.
Although it seems that the prognosis of patients who 
visit 1st grade institutions is poorer than that of patients 
who visit 5th grade institutions, we confirmed that 
improvement of PFT conduction is better in the former. 
In addition, while admission frequency in the former is 
about 10 times higher than in the latter, the mortality rate 
in 1st grade institutions is only about 2.5 times higher. 
This implies that the mortality risk of patients admitted 
to 1st grade institutions is only about one quarter of that 
of those admitted to 5th grade institutions. We found 
that institutions highly rated by HIRA showed a better 
prognosis than those rated lower. Therefore, we need to 
encourage clinicians to improve COPD management 
protocols as suggested by HIRA to improve their rat-
ing because it will help improve the prognosis of COPD 
patients.
The NAS group was younger and consisted of more 
females compared to the AS group. The NAS group might 
include mild COPD patients who did not need COPD 
medication regularly. Because aging and smoking history 
are critical factors for development and progression of 
COPD, young female patients might have relatively mild 
Fig. 3 Comparison of annual changes of PFT conduction rate (a), inhaled LAMA prescription rate (b), and admission frequency (c) and all‑cause 
mortality (d) between CQAP enrolled patients who visited the “1st grade” medical institution and those who visited the “5th grade” institution. PFT, 
pulmonary function test; COPD, chronic obstructive pulmonary disease. CQAP, COPD quality assessment program, LAMA, long‑acting muscarine 
antagonists
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COPD. Additionally, female COPD patients might be 
ashamed and afraid to be diagnosed with COPD. Then, 
they may not visit the hospital or be frequently medi-
cated for COPD. We speculated these reasons might lead 
to NAS group to be predominantly consisting of young 
females.
The percentage of prescribed ICS in the AS and NAS 
groups was similar, whereas percentage of prescribed 
bronchodilator in the AS group is higher than that in the 
NAS group. This could mean that the NAS group did not 
have proper management (including bronchodilator), and 
they used ICS or oral medication to relieve their symp-
toms. Additionally, we did not exclude asthma patients to 
clarify real-world characteristics of COPD. Consequently, 
these might lead to a high percentage of prescribed ICS.
This study has strengths from several perspectives. 
First, this is the first study to reveal a positive influence 
of the national health insurance program and the CQAP, 
and an improvement in the overall prognosis of COPD 
using four different study designs. Second, we assessed 
the complete national insurance cohort HIRA database 
to reduce selection bias. Third, it reveals the multi-fac-
eted positive influences of the CQAP using a variety of 
study designs.
This study has some limitations. First, COPD patients 
were defined with diagnostic codes only. Second, this 
study was not designed with randomization; thus, the 
direct effects of the CQAP could not be ascertained. 
Third, the study results should not be interpreted broadly 
for application in countries that do not implement a 
national medical insurance system. Fourth, there is the 
possibility of an unmeasured negative impact of the 
CQAP (example: the intentional removal or insertion of 
diagnostic codes, over-prescription of COPD medica-
tions, and avoidance of non-adherent patients). Last, we 
did not define COPD exacerbation by medication use 
including antibiotics or steroids.
Conclusions
We found a positive influence of the CQAP conducted by 
government on both the patient management protocol 
and prognosis of COPD in Korea. The CQAP was found 
to be effective overall, but restricted to the annual assess-
ment term. Thus, we believe that the continued applica-
tion of this type of quality assessment program will help 
improve clinical outcomes and medical utilization for 
COPD patients.
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